Contrasting Moolec Science (MLEC) and Its Competitors

Moolec Science (NASDAQ:MLEC) is one of 499 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Moolec Science to related businesses based on the strength of its valuation, institutional ownership, profitability, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Moolec Science and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-6,866.35%	-99.19%	-26.07%

Earnings & Valuation

This table compares Moolec Science and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.45
Moolec Science Competitors	$1.57 billion	$44.19 million	125.39

Moolec Science’s rivals have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Moolec Science has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s rivals have a beta of 1.20, indicating that their average share price is 20% more volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 33.8% of shares of all “Biotechnology” companies are held by institutional investors. 19.9% of Moolec Science shares are held by insiders. Comparatively, 20.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Moolec Science and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	1018	2956	7411	147	2.58

Moolec Science presently has a consensus price target of $6.00, indicating a potential upside of 574.16%. As a group, “Biotechnology” companies have a potential upside of 23.84%. Given Moolec Science’s stronger consensus rating and higher possible upside, analysts clearly believe Moolec Science is more favorable than its rivals.

Summary

Moolec Science rivals beat Moolec Science on 8 of the 13 factors compared.

Moolec Science Company Profile

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.